Drug Profile
VAX-DC/MM
Alternative Names: Dendritic cell vaccine - VaxCell BioLatest Information Update: 19 Mar 2021
Price :
$50
*
At a glance
- Originator Vaxcell-Bio Therapeutics
- Class Antineoplastics; Cancer vaccines; Dendritic cell vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Multiple myeloma
Most Recent Events
- 19 Mar 2021 Phase-IIb development is ongoing for Multiple myeloma in South Korea (Intradermal) (VaxCell-Bio Therapeutics pipeline, March 2021)
- 16 Jul 2018 Phase-II clinical trials in Multiple myeloma in South Korea (Intradermal) (VaxCell-Bio Therapeutics pipeline, July 2018)
- 14 Jun 2018 Pharmacodynamics data from preclinical trial in Multiple myeloma presented at the 23rd Congress of the European Haematology Association (EHA-2018)